New antibodies approved for immunological cancer therapy

New antibodies for immunological cancer therapy have been approved in Germany. These antibody therapies support tumor-specific immune cells in their fight against tumor cells. These are so-called checkpoint inhibitor antibodies: the PD-1 antibody (nivolumab / trade name: Opdivo®) and the PD-L-1 antibody (pembrolizumab / trade name: Keytruda®),